Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$6 Mln
Net Profit (TTM)
$2 Mln
ROE
-1.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
-2.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.1
Face value
--
Shares outstanding
12,232,600
CFO
$-251.02 Mln
EBITDA
$-264.40 Mln
Net Profit
$-266.79 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bellerophon Therapeutics (BLPH)
| -67.6 | -- | -- | -67.6 | -84.4 | -70.8 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Bellerophon Therapeutics (BLPH)
| -95.9 | -71.0 | -53.5 | 27.2 | -56.4 | -68.7 | 396.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide... delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Read more
President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director
Mr. Craig R. Jalbert CIRA
President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director
Mr. Craig R. Jalbert CIRA
Headquarters
Warren, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bellerophon Therapeutics Inc (BLPH) is $0.01 (NASDAQ) as of 18-Dec-2024 12:51 EDT. Bellerophon Therapeutics Inc (BLPH) has given a return of -84.45% in the last 3 years.
Since, TTM earnings of Bellerophon Therapeutics Inc (BLPH) is negative, P/E ratio is not available.
The P/B ratio of Bellerophon Therapeutics Inc (BLPH) is 0.04 times as on 18-Dec-2024, a 99 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.43
|
3.39
|
|
2021
|
-1.66
|
1.36
|
|
2020
|
-2.56
|
1.66
|
|
2019
|
-0.12
|
0.45
|
|
2018
|
1.24
|
0.90
|
The 52-week high and low of Bellerophon Therapeutics Inc (BLPH) are Rs -- and Rs -- as of 03-Apr-2026.
Bellerophon Therapeutics Inc (BLPH) has a market capitalisation of $ 0 Mln as on 18-Dec-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Bellerophon Therapeutics Inc (BLPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.